[go: up one dir, main page]

WO2021249367A1 - 二氮杂双环类化合物的对甲苯磺酸盐新晶型及其制备方法 - Google Patents

二氮杂双环类化合物的对甲苯磺酸盐新晶型及其制备方法 Download PDF

Info

Publication number
WO2021249367A1
WO2021249367A1 PCT/CN2021/098774 CN2021098774W WO2021249367A1 WO 2021249367 A1 WO2021249367 A1 WO 2021249367A1 CN 2021098774 W CN2021098774 W CN 2021098774W WO 2021249367 A1 WO2021249367 A1 WO 2021249367A1
Authority
WO
WIPO (PCT)
Prior art keywords
toluenesulfonate
crystal form
solvent
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2021/098774
Other languages
English (en)
French (fr)
Inventor
鲁霞
张晓宇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Crystal Pharmatech Co Ltd
Original Assignee
Crystal Pharmatech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crystal Pharmatech Co Ltd filed Critical Crystal Pharmatech Co Ltd
Priority to CN202180081891.6A priority Critical patent/CN116802183A/zh
Priority to US18/041,211 priority patent/US20240018155A1/en
Publication of WO2021249367A1 publication Critical patent/WO2021249367A1/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Definitions

  • the present invention relates to the field of chemical medicine, in particular to a new crystal form of p-toluene sulfonate of a diazabicyclic compound and a preparation method thereof.
  • [(1S)-2,2-Difluorocyclopropyl][(1R,5S)-3- ⁇ 2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl ⁇ -3,8-Diazabicyclo[3.2.1]octane-8-yl]methanone is a dual inhibitor of JAK1 and TYK2, which has shown certainty in the treatment of certain inflammatory and autoimmune diseases Efficacy, it is currently being tested for the treatment of alopecia areata, psoriasis and ulcerative colitis. Its structure is as follows:
  • Patent US96663526B2 discloses formula (I) and its enantiomers.
  • the main application in clinical trials is the S configuration of the compound and its S configuration p-toluenesulfonate (Andrew F., Catherine MA and et al. , J. Med. Chem. 2018, 61, 8597-8612.), there is no report on the crystalline form of the compound p-toluenesulfonate.
  • the different crystal forms of solid chemical drugs can cause differences in their stability, solubility, safety, etc., and then affect the absorption and bioavailability of the drug. Therefore, conducting comprehensive and systematic polymorphic screening in drug development and selecting the most suitable crystal form for development is one of the important research contents that cannot be ignored.
  • the invention provides a new crystal form of formula (I) p-toluenesulfonate and its preparation method and application.
  • the p-toluenesulfonate crystalline form A described in 1 above has X-ray powder diffraction at one or two of the 2 ⁇ values of 19.1° ⁇ 0.2°, 14.1° ⁇ 0.2°, 21.5° ⁇ 0.2° or There are three characteristic peaks.
  • the p-toluenesulfonate crystal form A described in 1 or 2 above has characteristic peaks at 2 ⁇ values of 19.1° ⁇ 0.2°, 14.1° ⁇ 0.2°, and 21.5° ⁇ 0.2° by X-ray powder diffraction.
  • the p-toluenesulfonate salt of the compound of formula (I) is dissolved in a normal solvent, and after filtration, an anti-solvent is added dropwise thereto to obtain p-toluenesulfonate crystal form A.
  • the p-toluenesulfonate salt of the compound of formula (I) is dissolved in a normal solvent, and after filtration, it is quickly added to the anti-solvent to obtain p-toluenesulfonate crystal form A.
  • the p-toluenesulfonate salt of the compound of formula (I) is dissolved in a positive solvent, and then placed in a sealed environment containing an anti-solvent for osmotic crystallization to obtain p-toluenesulfonate crystal form A.
  • the p-toluenesulfonate salt of the compound of formula (I) is dissolved in a positive solvent, and the solution is balanced under high temperature conditions and then filtered, and the temperature is lowered until a solid precipitates to obtain p-toluenesulfonate crystal form A.
  • a pharmaceutical composition comprising the crystal described in any one of 1 to 3 above and a pharmaceutically acceptable carrier.
  • a pharmaceutical composition having JAK1 and TYK2 pathway dual inhibitor activity which contains the crystal described in any one of 1 to 3 above as an active ingredient.
  • a prophylactic or therapeutic agent for the treatment of alopecia areata, psoriasis, and ulcerative colitis, which contains the crystals described in any one of 1 to 3 above as an active ingredient.
  • the formula (I) p-toluenesulfonate crystal form A provided by the invention has the advantages of solubility, melting point, stability, dissolution, moisture absorption, adhesion, fluidity, bioavailability and processing There are advantages in at least one aspect of performance, purification, preparation production, safety, etc., providing a new and better choice for the preparation of drug preparations with dual inhibitors of JAK1 and TYK2 pathways, which is very important for drug development significance.
  • the X-ray powder diffraction has characteristic peaks at one or two or three of the 2 ⁇ values of 19.1° ⁇ 0.2°, 14.1° ⁇ 0.2°, and 21.5° ⁇ 0.2°.
  • the X-ray powder diffraction has characteristic peaks at 2 ⁇ values of 19.1° ⁇ 0.2°, 14.1° ⁇ 0.2°, and 21.5° ⁇ 0.2°.
  • the X-ray powder diffraction has characteristic peaks at one or two or three of the 2 ⁇ values of 22.5° ⁇ 0.2°, 19.8° ⁇ 0.2°, and 16.7° ⁇ 0.2°.
  • the X-ray powder diffraction has characteristic peaks at 2 ⁇ values of 22.5° ⁇ 0.2°, 19.8° ⁇ 0.2°, and 16.7° ⁇ 0.2°.
  • the X-ray powder diffraction has a 2 ⁇ value of 6.2° ⁇ 0.2°, 18.6° ⁇ 0.2°, 9.3° ⁇ 0.2°, 19.1° ⁇ 0.2°, 14.1° ⁇ 0.2°, 21.5° There are characteristic peaks at any 4, or 5, or 6, or 7, or 8, or 9 of ⁇ 0.2°, 22.5° ⁇ 0.2°, 19.8° ⁇ 0.2°, 16.7° ⁇ 0.2°.
  • the X-ray powder diffraction has a 2 ⁇ value of 6.2° ⁇ 0.2°, 18.6° ⁇ 0.2°, 9.3° ⁇ 0.2°, 19.1° ⁇ 0.2°, 14.1° ⁇ 0.2°, 21.5° There are characteristic peaks at ⁇ 0.2°, 22.5° ⁇ 0.2°, 19.8° ⁇ 0.2°, and 16.7° ⁇ 0.2°.
  • FIG. 1 its X-ray powder diffraction pattern is shown in FIG. 1.
  • the method for preparing p-toluenesulfonate crystal form A is characterized in that the p-toluenesulfonate salt of the compound of formula (I) is dissolved in a normal solvent, and after filtration, an anti-solvent is added dropwise thereto to obtain p-toluenesulfonate Salt crystal form A,
  • the positive solvent is selected from methanol, dichloromethane, N,N-dimethylacetamide, dimethylsulfoxide and a mixed solvent of the above solvents.
  • the anti-solvent is selected from esters, alcohols, ethers, alkanes, aromatic hydrocarbons, and ketones.
  • the ester solvent is isopropyl acetate and ethyl acetate
  • the alcohol solvent is isopropanol
  • the ether solvent is methyl tert-butyl ether and tetrahydrofuran.
  • the alkane solvent is n-heptane
  • the aromatic hydrocarbon solvent is toluene
  • the ketone solvent is acetone.
  • the anti-solvent addition temperature is 22°C to 28°C.
  • the method for preparing p-toluenesulfonate crystal form A is characterized in that the p-toluenesulfonate salt of the compound of formula (I) is dissolved in a positive solvent, and after filtration, it is quickly added to the anti-solvent, if not directly precipitated Crystal, the sample is placed at a certain temperature for solid precipitation to obtain p-toluenesulfonate crystal form A, the positive solvent is selected from dichloromethane, N,N-dimethylacetamide, the anti-solvent is selected From alcohols, ethers, esters and aromatic hydrocarbons.
  • the alcohol is isopropanol
  • the ether is methyl tert-butyl ether
  • the ester is isopropyl acetate
  • the aromatic hydrocarbon is The class is toluene.
  • the dissolution temperature is 22°C to 28°C.
  • the addition temperature is 22°C to 28°C.
  • the standing temperature is -25°C to -10°C, for example, -20°C.
  • the preparation method of the p-toluene sulfonate crystal form A is characterized in that the p-toluene sulfonate salt of the compound of formula (I) is dissolved in a volatile solvent at a certain temperature and volatilized and crystallized to obtain crystal form A, wherein
  • the volatile solvent is a single solvent or mixed solvent of alcohols, halogenated hydrocarbons, ethers, aromatic hydrocarbons, and water.
  • the alcohol solvent is methanol, ethanol, isopropanol, preferably methanol
  • the halogenated hydrocarbon solvent is chloroform or dichloromethane
  • the ether solvent is tetrahydrofuran
  • the The aromatic hydrocarbon solvent is toluene.
  • the mixed solvent is selected from at least one of methanol/toluene or tetrahydrofuran/water.
  • the volume ratio of methanol/toluene is 4:1, and the volume ratio of tetrahydrofuran/water is 1:1.
  • the dissolution and volatilization temperature is 0°C to 60°C, preferably 5°C to 50°C.
  • the polymer is added and volatilized until a solid is precipitated, and the p-toluenesulfonate crystal form A is obtained.
  • the high polymer is at least one of poloxamer, polyvinylpyrrolidone, methylcellulose, polyvinyl alcohol, acrylic resin, sodium carboxymethylcellulose, and hydroxypropyl- ⁇ -cyclodextrin.
  • the mass ratio of the polymer to the compound of formula (I) is 1:4-10, or 1:6-8.
  • the preparation method of the p-toluenesulfonate crystal form A is characterized in that the p-toluenesulfonate salt of the compound of formula (I) is dissolved in a positive solvent, and then placed in a sealed environment containing an anti-solvent for osmotic crystallization , The crystal form A of p-toluenesulfonate salt is obtained.
  • the normal solvent is a single or mixed solvent of methanol, toluene, and ethanol
  • the anti-solvent is selected from methyl tert-butyl ether and acetone.
  • the positive solvent is selected from at least one of methanol/toluene and methanol/ethanol.
  • the volume ratio of methanol/toluene is 1 ⁇ 4:1, and the volume ratio of methanol/ethanol is 1:1.
  • the dissolution and permeation temperature is 20°C to 30°C.
  • the preparation method of the p-toluenesulfonate crystal form A is characterized in that the p-toluenesulfonate of the compound of formula (I) is dissolved in an organic solvent at a high temperature, and a solid is precipitated after being reduced to a low temperature to obtain p-toluenesulfonic acid Salt crystal form A, wherein the organic solvent is a single solvent or a mixed solvent of methanol, ethanol, and acetone.
  • the mixed solvent is methanol/acetone.
  • the volume ratio of methanol/acetone is 1:1.
  • the high temperature is 40°C to 60°C.
  • the precipitation temperature is -20°C to 5°C.
  • the cooling is rapid cooling.
  • the temperature reduction is from 0.05°C/min to 0.5°C/min.
  • the formula (I) and/or its p-toluenesulfonate as a raw material refers to its solid (crystalline or amorphous), semi-solid, wax or oil form.
  • the raw material compound and/or p-toluenesulfonic acid and its salt are in the form of solid powder.
  • the "stirring" is accomplished by conventional methods in the art, such as magnetic stirring or mechanical stirring, at a stirring speed of 50-1800 revolutions per minute, where magnetic stirring is preferably 300-900 revolutions per minute, and mechanical stirring is preferably 100- 300 revolutions per minute.
  • crystalline or “polymorphic” refers to what is confirmed by the characterization of the X-ray diffraction pattern shown.
  • the physical and chemical properties discussed here can be characterized, and the experimental error depends on the condition of the instrument, the preparation of the sample, and the purity of the sample.
  • the X-ray diffraction pattern usually changes with the conditions of the instrument.
  • the relative intensity of the X-ray diffraction pattern may also change with changes in experimental conditions, so the order of peak intensities cannot be the only or decisive factor.
  • the relative intensity of the diffraction peaks in the XRPD spectrum is related to the preferred orientation of the crystal.
  • the peak intensities shown in this article are illustrative and not for absolute comparison.
  • the experimental error of the peak angle is usually 5% or less, and the error of these angles should also be taken into account, and the error of ⁇ 0.2° is usually allowed.
  • the overall peak angle will be shifted, and a certain shift is usually allowed.
  • the X-ray diffraction pattern of a crystal form in the present invention does not have to be exactly the same as the X-ray diffraction pattern in the example referred to here, and the "XRPD pattern is the same" as used herein does not mean absolutely the same.
  • the same peak position can differ by ⁇ 0.2° and the peak intensity allows certain variability. Any crystal form having a pattern identical or similar to the characteristic peaks in these patterns falls within the scope of the present invention.
  • Those skilled in the art can compare the spectrum listed in the present invention with a spectrum of an unknown crystal form to confirm whether the two sets of spectra reflect the same or different crystal forms.
  • the p-toluenesulfonate crystal form A of the present invention is pure and single, and substantially no other crystal forms are mixed.
  • substantially no when used to refer to a new crystal form means that this crystal form contains less than 20% by weight of other crystal forms, especially less than 10% by weight of other crystal forms, and even less. Other crystal forms that are less than 5% by weight, and even other crystal forms that are less than 1% by weight.
  • room temperature usually means 22-28°C unless otherwise specified.
  • the X-ray powder diffraction pattern of the present invention is collected on a PANalytacal X'Pert 3-ray powder diffractometer.
  • the parameters of the X-ray powder diffraction method described in the present invention are as follows:
  • Scan range: from 3.0 to 40.0 degrees
  • the differential scanning calorimetry analysis of the present invention is collected on the Q2000 and Discovery Q2500 models of TA Company.
  • the method parameters of the differential scanning calorimetry analysis of the present invention are as follows:
  • thermogravimetric analysis curve described in the present invention is collected on the Q5000 and Discovery Q5500 models of TA Company.
  • the method parameters of the thermogravimetric analysis of the present invention are as follows:
  • the dynamic moisture adsorption map of the present invention is collected on the Intrinsic and Intrinsic Plus dynamic moisture adsorption instruments of SMS Company.
  • the method parameters of the dynamic moisture adsorption test described in the present invention are as follows:
  • Relative humidity range 0%RH-95%RH-0%RH relative humidity gradient: 10% (0%RH-90%RH-0%RH), 5% (90%RH-95%RH and 95%RH- 90%RH)
  • the particle size distribution results described in the present invention are collected on the S3500 laser particle size analyzer of Microtrac Company.
  • Microtrac S3500 is equipped with SDC (Sample Delivery Controller) sampling system.
  • SDC Sample Delivery Controller
  • This test adopts the wet method, and the test dispersion medium is Isopar G (containing 0.2% lecithin).
  • the method parameters of the laser particle size analyzer are as follows:
  • Particle size distribution volume distribution Acquisition time: 10 seconds
  • the inherent dissolution rate data described in the present invention is collected on the Agilent 708DS dissolution apparatus of Agilent Company.
  • the inherent dissolution test conditions are as follows:
  • the polarizing microscope photos described in the present invention are collected by Zeiss microscope AxioScope.A1 at room temperature, the microscope is equipped with Axiocam 305 color camera and 5 ⁇ , 10 ⁇ , 20 ⁇ and 50 ⁇ objective lenses.
  • the compound (I) and its p-toluenesulfonate starting material used in the following examples can be prepared according to the prior art, but the starting crystal form is not a limiting condition for preparing the crystal form of the present invention.
  • the solid obtained in this example is p-toluenesulfonate crystal form A.
  • the X-ray powder diffraction data of p-toluenesulfonate crystal form A is shown in Table 1, and its diffraction pattern is shown in Fig. 1.
  • 1 H NMR is shown in Figure 2, the molar ratio of free base to p-toluenesulfonic acid is 1:1, and no solvent remains.
  • the solid obtained in this example is p-toluenesulfonate crystal form A.
  • the X-ray powder diffraction data of p-toluenesulfonate crystal form A is shown in Table 2, and its diffraction pattern is shown in Fig. 3.
  • the TGA is shown in Figure 4, and the DSC is shown in Figure 5.
  • the melting point is about 280°C.
  • the crystal form A of p-toluenesulfonate salt is crystal-free.
  • the solids obtained in this example are all p-toluenesulfonate crystal form A.
  • the detailed test conditions involved in this example are shown in Table 3.
  • the X-ray powder diffraction data of the sample of Example 3 is shown in Table 4.
  • the solids obtained in this example are all p-toluenesulfonate crystal form A.
  • the detailed test conditions involved in this example are shown in Table 5.
  • the X-ray powder diffraction data of the sample of Example 7 is shown in Table 6.
  • the solids obtained in this example are all p-toluenesulfonate crystal form A.
  • the detailed test conditions involved in this example are shown in Table 8, the X-ray powder diffraction data of the sample of Example 11 is shown in Table 9, and the diffraction pattern is shown in Fig. 6.
  • the solids obtained in this example are all p-toluenesulfonate crystal form A.
  • the detailed test conditions involved in this example are shown in Table 10, and the X-ray powder diffraction data of the sample of Example 13 is shown in Table 11.
  • the solids obtained in this example are all p-toluenesulfonate crystal form A.
  • the detailed test conditions involved in this example are shown in Table 12, the X-ray powder diffraction data of Example 23 is shown in Table 13, and the diffraction pattern is shown in Fig. 7.
  • the solids obtained in this example are all p-toluenesulfonate crystal form A.
  • the detailed test conditions involved in this example are shown in Table 14, and the X-ray powder diffraction data of the sample of Example 27 is shown in Table 15.
  • the solids obtained in this example are all p-toluenesulfonate crystal form A.
  • the detailed test conditions involved in this example are shown in Table 16.
  • the X-ray powder diffraction data of the sample of Example 33 is shown in Table 17.
  • the crystal form A of the present invention is placed for 8 weeks under the conditions of 25°C/60%RH and 40°C/75%RH, the crystal form remains unchanged, and the purity is greater than 99%.
  • the crystal form A of the present invention has better physical/chemical stability under the conditions of 25°C/60%RH and 40°C/75%RH.
  • moisture-absorbing weight gain is not less than 15%
  • moisture absorption weight gain is less than 15% but not less than 2%
  • moisture absorption weight gain is less than 2% but not less than 0.2%
  • the p-toluenesulfonate crystal form A prepared by the method of Example 1 of the present invention and the prior art solid were used SGF (simulated artificial gastric fluid), FaSSIF (artificial intestinal fluid under fasting state), FeSSIF (artificial intestinal fluid under full fed state) Prepare a suspension with pure water respectively, and filter after equilibrating for 1 hour, 2 hours, 4 hours and 24 hours to obtain a saturated solution.
  • the content of the sample in the saturated solution was determined by high performance liquid chromatography (HPLC). It can be seen from the results that the solubility of crystal form A of the present invention in pure water, SGF, FaSSIF and FeSSIF is shown in Table 19.
  • the crystal form A of the present invention has good solubility in biological media and can meet the requirements of drug solubility for oral administration. Compared with the prior art, the crystal form A has better solubility and has better application prospects.
  • the tensile strength of crystal form A is calculated to be 1.9 MPa, which has a higher tensile strength than the existing Compared with the technology, it has better compressibility and can meet the technological requirements of pharmaceutical preparations.
  • crystal form A prepared by the method of Example 1 of the present invention and the prior art solid on a glass slide, add a little vacuum silicone oil dropwise to disperse the sample, then cover the cover glass and place it under a polarizing microscope observe.
  • the crystal form of the present invention is a short rod-shaped solid with good fluidity ( Figure 11).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

一种式（I）所示的二氮杂双环类化合物的对甲基苯磺酸盐晶型A及其制备方法。式（I）所示化合物的对甲基苯磺酸盐晶型A在溶解度、熔点、稳定性、溶出度、引湿性、黏附性、流动性、生物有效性以及加工性能、提纯作用、制剂生产、安全性等方面中的至少一方面上存在优势，可用于预防或治疗斑秃、银屑病和溃疡性结肠炎。

Description

二氮杂双环类化合物的对甲苯磺酸盐新晶型及其制备方法 技术领域
本发明涉及化学医药领域，特别是涉及一种二氮杂双环类化合物的对甲基苯磺酸盐的新晶型及其制备方法。
背景技术
[(1S)-2,2-二氟环丙基][(1R，5S)-3-{2-[(1-甲基-1H-吡唑-4-基)氨基]嘧啶-4-基}-3,8-二氮杂双环[3.2.1]辛烷-8-基]甲酮是一种JAK1和TYK2双重抑制剂，在治疗某些炎性和自身免疫性疾病上显示出一定的功效，目前正试验用于治疗斑秃、银屑病和溃疡性结肠炎等治疗，其结构如下所示:
Figure PCTCN2021098774-appb-000001
专利US9663526B2中公开了式(I)及其对映异构体，临床试验中主要应用的是化合物的S构型及其S构型的对甲苯磺酸盐(Andrew F.,Catherine M.A.and et al,J.Med.Chem.2018,61,8597-8612.)，目前尚无该化合物对甲苯磺酸盐的晶型的报道。
固体化学药物晶型不同，可造成其稳定性、溶解度、安全性等方面的差异，进而影响药物的吸收和生物利用度。因此，药物研发中进行全面系统的多晶型筛选，选择最适合开发的晶型，是不可忽视的重要研究内容之一。
发明内容
本发明提供了式(I)对甲苯磺酸盐的新晶型及其制备方法和用途。
1.式(I)所示化合物[(1S)-2,2-二氟环丙基][(1R，5S)-3-{2-[(1-甲基-1H-吡唑-4-基)氨基]嘧啶-4-基}-3,8-二氮杂双环[3.2.1]辛烷-8-基]甲酮的对甲基苯磺酸盐A型晶体、即对甲苯磺酸盐晶型A，其特征在于，使用Cu-Kα辐射，所述对甲苯磺酸盐晶型A的X射线粉末衍射在2θ值为6.2°±0.2°,18.6°±0.2°,9.3°±0.2°处有特征峰，
Figure PCTCN2021098774-appb-000002
2.上述1所述的对甲苯磺酸盐晶型A，其X射线粉末衍射在2θ值为19.1°±0.2°, 14.1°±0.2°,21.5°±0.2°中的一处或两处或三处有特征峰。
3.上述1或2所述的对甲苯磺酸盐晶型A，其X射线粉末衍射在2θ值为19.1°±0.2°,14.1°±0.2°,21.5°±0.2°处有特征峰。
4.上述1～3中任意一项所述的对甲苯磺酸盐晶型A的制备方法，其特征在于，
Figure PCTCN2021098774-appb-000003
将式(I)化合物的对甲苯磺酸盐溶解于正溶剂中，过滤后向其中逐滴加入反溶剂，得到对甲苯磺酸盐晶型A。
5.上述1～3中任意一项所述的对甲苯磺酸盐晶型A的制备方法，其特征在于，
Figure PCTCN2021098774-appb-000004
将式(I)化合物的对甲苯磺酸盐溶解于正溶剂中，过滤后将其快速加入反溶剂中，得到对甲苯磺酸盐晶型A。
6.上述1～3中任意一项所述的对甲苯磺酸盐晶型A的制备方法，其特征在于，
Figure PCTCN2021098774-appb-000005
一定温度下将式(I)化合物的对甲苯磺酸盐溶解于挥发性溶剂中，挥发析晶，得到对甲苯磺酸盐晶型A。
7.上述1～3中任意一项所述的对甲苯磺酸盐晶型A的制备方法，其特征在于，
Figure PCTCN2021098774-appb-000006
将式(I)化合物的对甲苯磺酸盐溶于正溶剂中，然后置于含有反溶剂的密封环境中，渗透析晶，得到对甲苯磺酸盐晶型A。
8.上述1～3中任意一项所述的对甲苯磺酸盐晶型A的制备方法，其特征在于，
Figure PCTCN2021098774-appb-000007
将式(I)化合物的对甲苯磺酸盐溶于正溶剂中，高温条件下溶解平衡后过滤，降温至析出固体，得到对甲苯磺酸盐晶型A。
9药物组合物，其包含上述1～3中任一项所述的晶体和制药学可接受的载体。
10.具有JAK1和TYK2通路双重抑制剂活性的药物组合物，其含有上述1～3中任一项所述的晶体作为有效成分。
11.治疗斑秃、银屑病和溃疡性结肠炎的预防药或治疗药，其含有上述1～3中任一项所述的晶体作为有效成分。
与现有技术相比，发明提供的式(I)对甲基苯磺酸盐晶型A，在溶解度、熔点、稳定性、溶出度、引湿性、黏附性、流动性、生物有效性以及加工性能、提纯作用、制剂生产、安全性等方面中的至少一方面上存在优势，为JAK1和TYK2通路双重抑制剂的药物制剂的制备提供了新的更好的选择，对于药物开发具有非常重要的意义。
附图说明
图1实施例1中对甲苯磺酸盐晶型A的X射线粉末衍射图
图2实施例1中对甲苯磺酸盐的液态核磁氢谱图谱
图3实施例2中对甲苯磺酸盐晶型A的X射线粉末衍射图
图4实施例2中对甲苯磺酸盐晶型A的热重分析曲线
图5实施例2中对甲苯磺酸盐晶型A的差式扫描量热曲线
图6实施例11中对甲苯磺酸盐晶型A的X射线粉末衍射图
图7实施例23中对甲苯磺酸盐晶型A的X射线粉末衍射图
图8实施例39中对甲苯磺酸盐晶型A稳定性的X射线粉末衍射对比图
图9实施例40中对甲苯磺酸盐晶型A的动态水分吸附曲线
图10实施例40中对甲苯磺酸盐晶型A的动态水分吸附测试前后的X射线粉末衍射图
图11实施例44中对甲苯磺酸盐晶型A的偏光显微照片
具体实施方式
式(I)所示化合物[(1S)-2,2-二氟环丙基][(1R，5S)-3-{2-[(1-甲基-1H-吡唑-4-基)氨基]嘧啶-4-基}-3,8-二氮杂双环[3.2.1]辛烷-8-基]甲酮的对甲苯磺酸盐A型晶体、即对甲苯磺酸盐晶型A，其特征在于，使用Cu-Kα辐射，所述晶型A的X射线粉末衍射在2θ值为6.2°±0.2°,18.6°±0.2°,9.3°±0.2°处有特征峰，
Figure PCTCN2021098774-appb-000008
在本发明的一个实施方式中，其X射线粉末衍射在2θ值为19.1°±0.2°,14.1°±0.2°,21.5°±0.2°中的一处或两处或三处有特征峰。
在本发明的一个实施方式中，其X射线粉末衍射在2θ值为19.1°±0.2°,14.1°±0.2°,21.5°±0.2°处有特征峰。
在本发明的一个实施方式中，其X射线粉末衍射在2θ值为22.5°±0.2°,19.8°±0.2°,16.7°±0.2°中的一处或两处或三处有特征峰。
在本发明的一个实施方式中，其X射线粉末衍射在2θ值为22.5°±0.2°,19.8°±0.2°,16.7°±0.2°处有特征峰。
在本发明的一个实施方式中，其X射线粉末衍射在2θ值为6.2°±0.2°,18.6°±0.2°,9.3°±0.2°,19.1°±0.2°,14.1°±0.2°,21.5°±0.2°,22.5°±0.2°,19.8°±0.2°,16.7°±0.2°中的任意4处、或5处、或6处、或7处、或8处、或9处有特征峰。
在本发明的一个实施方式中，其X射线粉末衍射在2θ值为6.2°±0.2°,18.6°±0.2°,9.3°±0.2°,19.1°±0.2°,14.1°±0.2°,21.5°±0.2°,22.5°±0.2°,19.8°±0.2°,16.7°±0.2°处有特征峰。
在本发明的一个实施方式中，其X射线粉末衍射图如图1所示。
所述对甲苯磺酸盐晶型A的制备方法，其特征在于，将式(I)化合物的对甲苯磺酸盐溶解于正溶剂中，过滤后向其中逐滴加入反溶剂，得到对甲苯磺酸盐晶型A，所述正溶剂选自甲醇、二氯甲烷、N,N-二甲基乙酰胺、二甲亚砜以及上述溶剂的混合溶剂。所述反溶剂选自酯类、醇类、醚类、烷烃类、芳香烃类、酮类。
在本发明的一个实施方式中，所述酯类溶剂为乙酸异丙酯、乙酸乙酯、所述醇类溶剂为异丙醇，所述醚类溶剂为甲基叔丁基醚、四氢呋喃，所述烷烃类溶剂为正庚烷，所述芳香烃类溶剂为甲苯，所述酮类溶剂为丙酮。
在本发明的一个实施方式中，所述反溶剂添加温度为22℃到28℃。
所述对甲苯磺酸盐晶型A的制备方法，其特征在于，将式(I)化合物的对甲苯磺酸盐溶解于正溶剂中，过滤后将其快速加入反溶剂中，如未直接析晶，则将样品静置于一定温度下待固体析出，得到对甲苯磺酸盐晶型A，所述正溶剂选自二氯甲烷、N,N-二甲基乙酰胺，所述反溶剂选自醇类、醚类、酯类和芳香烃类。
在本发明的一个实施方式中，所述醇类为异丙醇，所述醚类为甲基叔丁基醚、2-甲基四氢呋喃，所述酯类为乙酸异丙酯，所述芳香烃类为甲苯。
在本发明的一个实施方式中，所述溶解温度为22℃到28℃。
在本发明的一个实施方式中，过滤后在搅拌下快速加入至反溶剂中。
在本发明的一个实施方式中，加入温度为22℃到28℃。
在本发明的一个实施方式中，静置温度为-25℃到-10℃，例如为-20℃。
所述对甲苯磺酸盐晶型A的制备方法，其特征在于，一定温度下将式(I)化合物的对甲苯磺酸盐溶解于挥发性溶剂中，挥发析晶，得到晶型A，其中，挥发性溶剂为醇类、卤代烃类、醚类、芳香烃类、水的单一溶剂或混合溶剂。
在本发明的一个实施方式中，所述醇类溶剂为甲醇、乙醇、异丙醇，优先甲醇，所述卤代烃类溶剂为氯仿、二氯甲烷，所述醚类溶剂为四氢呋喃，所述芳香烃类溶剂为甲苯。
在本发明的一个实施方式中，所述混合溶剂选自甲醇/甲苯或四氢呋喃/水中的至少一种。
在本发明的一个实施方式中，甲醇/甲苯的体积比为4:1，四氢呋喃/水的体积比为1:1。
在本发明的一个实施方式中，所述溶解与挥发温度为0℃至60℃，优选5℃至50℃。
在本发明的一个实施方式中，所述溶解过滤后，加入高聚物挥发直至有固体析出，得到对甲苯磺酸盐晶型A。
所述高聚物为泊洛沙姆、聚乙烯吡咯烷酮、甲基纤维素、聚乙烯醇、丙烯酸树脂、羧甲基纤维素钠、羟丙基-β-环糊精中的至少一种。
所述高聚物与式(I)化合物的质量比为1:4～10，或者1:6～8。
所述对甲苯磺酸盐晶型A的制备方法，其特征在于，将式(I)化合物的对甲苯磺酸盐溶于正溶剂中，然后置于含有反溶剂的密封环境中，渗透析晶，得到对甲苯磺酸盐晶型A。
在本发明的一个实施方式中，所述正溶剂为甲醇、甲苯、乙醇的单一或混合溶剂，所述反溶剂选自甲基叔丁基醚、丙酮。
在本发明的一个实施方式中，所述正溶剂选自甲醇/甲苯、甲醇/乙醇中的至少一种。
在本发明的一个实施方式中，甲醇/甲苯的体积比为1～4:1，甲醇/乙醇的体积比为1:1。
在本发明的一个实施方式中，所述溶解与渗透温度为20℃至30℃。
所述对甲苯磺酸盐晶型A的制备方法，其特征在于，高温下将式(I)化合物的对甲苯磺酸盐溶解于有机溶剂中，降至低温后固体析出，得到对甲苯磺酸盐晶型A，其中，有机溶剂为甲醇、乙醇、丙酮的单一溶剂或混合溶剂。
在本发明的一个实施方式中，所述混合溶剂为甲醇/丙酮。
在本发明的一个实施方式中，甲醇/丙酮的体积比为1:1。
在本发明的一个实施方式中，所述高温为40℃到60℃。
在本发明的一个实施方式中，所述析出温度为-20℃到5℃。
在本发明的一个实施方式中，所述降温为快速降温。
在本发明的一个实施方式中，所述降温为降温速率0.05℃/分钟到0.5℃/分钟。
根据本发明，作为原料的所述式(I)和/或其对甲苯磺酸盐指其固体(晶体或无定形)、半固体、蜡或油形式。优选地，作为原料的化合物和/或对甲苯磺酸其盐为固体粉末形式。所述“搅拌”，采用本领域的常规方法完成，例如磁力搅拌或机械搅拌，搅拌速度为50-1800转/分钟，其中，磁力搅拌优选为300-900转/分钟，机械搅拌优选为100-300转/分钟。
本发明中，“晶体”或“多晶型”指的是被所示的X射线衍射图表征所证实的。本领域技术人员能够理解，这里所讨论的理化性质可以被表征，其中的实验误差取决于仪器的条件、样品的准备和样品的纯度。特别是，本领域技术人员公知，X射线衍射图通常会随着仪器的条件而有所改变。特别需要指出的是，X射线衍射图的相对强度也可能随着实验条件的变化而变化，所以峰强度的顺序不能作为唯一或决定性因素。事实上，XRPD图谱中衍射峰的相对强度与晶体的择优取向有关，本文所示的峰强度为说明性而非用于绝对比较。另外，峰角度的实验误差通常在5％或更少，这些角度的误差也应该被考虑进去，通常允许有±0.2°的误差。另外，由于样品厚度等实验因素的影响，会造成峰角度的整体偏移，通常允许一定的偏移。因而，本领域技术人员可以理解的是，本发明中一个晶型的X射线衍射图不必和这里所指的例子中的X射线衍射图完全一致，本文所述“XRPD图相同”并非指绝对相同，相同峰位置可相差±0.2°且峰强度允许一定可变性。任何具有和这些图谱中的特征峰相同或相似的图的晶型均属于本发明的范畴之内。本领域技术人员能够将本发明所列的图谱和一个未知晶型的图谱相比较，以证实这两组图谱反映的是相同还是不同的晶型。
在一些实施方案中，本发明的对甲苯磺酸盐晶型A是纯的、单一的，基本没有混合任何其他晶型。本发明中，“基本没有”当用来指新晶型时指这个晶型含有少于20％(重量)的其他晶型，尤其指少于10％(重量)的其他晶型，更指少于5％(重量)的其他晶型，更指少于1％(重量)的其他晶型。
需要说明的是，本发明中提及的数值及数值范围不应被狭隘地理解为数值或数值范围本身，本领域技术人员应当理解其可以根据具体技术环境的不同，在不背离本发明精神和原则的基础上围绕具体数值有所浮动，本发明中，这种本领域技术人员可预见的浮动范围多以术语“约”来表示。
本发明说明书中记载的数值范围的上限值和下限值可以任意地组合
实施例
以下将通过具体实施例进一步阐述本发明，但并不用于限制本发明的保护范围。本领域技术人员可在权利要求范围内对制备方法和使用仪器作出改进，这些改进也应视为本发明的保护范围。因此，本发明专利的保护范围应以所附权利要求为准。
本发明中“室温”如无特别说明，通常是指22～28℃。
本发明中所用到的缩写的解释如下：
XRPD：X射线粉末衍射
DSC：差示扫描量热分析
TGA：热重分析
1H NMR：液态氢谱核磁
本发明所述的X射线粉末衍射图在PANalytacal X’ Pert3射线粉末衍射仪上采集。本发明所述的X射线粉末衍射的方法参数如下：
X射线光源：Cu,Kα
Kα1
Figure PCTCN2021098774-appb-000009
1.540598；Kα2
Figure PCTCN2021098774-appb-000010
1.544426
Kα2/Kα1强度比例：0.50
电压：45仟伏特(kV)
电流：40毫安培(mA)
扫描范围：自3.0至40.0度
本发明所述的差示扫描量热分析在TA公司的Q2000型及Discovery Q2500型上采集。本发明所述的差示扫描量热分析的方法参数如下：
扫描速率：10℃/min
保护气体：氮气
本发明所述的热重分析曲线在TA公司Q5000型及Discovery Q5500型上采集。本发明所述的热重分析的方法参数如下：
扫描速率：10℃/min
保护气体：氮气
本发明所述的动态水分吸附图在SMS公司的Intrinsic型及Intrinsic Plus型动态水分吸附仪上采集。本发明所述的动态水分吸附测试的方法参数如下：
温度：25℃
保护气体及流量：N 2，200毫升/分钟
dm/dt：0.002％/分钟
最小dm/dt平衡时间：10分钟
最大平衡时间：180分钟
相对湿度范围：0％RH-95％RH-0％RH相对湿度梯度：10％(0％RH-90％RH-0％RH)、5％(90％RH-95％RH和95％RH-90％RH)
本发明中所述的粒径分布结果是在Microtrac公司的S3500型激光粒度分析仪上采集。Microtrac S3500配备SDC(Sample Delivery Controller)进样系统。本测试采用湿法，测试分散介质为Isopar G(含0.2％卵磷脂)。所述的激光粒度分析仪的方法参数如下：
粒度分布：体积分布 采集时间：10秒
分散介质：Isopar G 粒度坐标：标准
采集次数：3次 分散介质折射率：1.42
透明度：透明 残差：启用
颗粒折射率：1.59 流速：60％*
颗粒形状：不规则 过滤：启用
超声功率：30瓦 超声时间：超声30秒
*：流速60％为65毫升/s的60％
本发明中所述的固有溶出速率数据是在Agilent公司的Agilent 708DS型溶出仪上采集。所述的固有溶出测试条件如下：
溶出仪 Agilent 708DS
方法 浆法
介质 pH 6.8磷酸盐缓冲液
介质体积 900毫升
转速 100转/分
介质温度 37℃
取样点 1,2,3,4,5,10,15,20,25,30分钟
补充介质 No
本发明中所述的偏光显微镜照片是通过蔡司显微镜Axio Scope.A1在室温条件下采集，显微镜配备Axiocam 305彩色相机以及5×、10×、20×和50×物镜。
下述实施例中所使用的化合物(I)及其对甲苯磺酸盐起始物可根据现有技术制备得到，但起始晶型并非制备本发明晶型的限定条件。
实施例1：对甲苯磺酸盐晶型A的制备
室温条件下称取10.1毫克式(I)对甲苯磺酸盐化合物置于3毫升的玻璃小瓶中，加入1.0毫升甲醇得到悬浊液。将该悬浊液在50℃条件下磁力搅拌(转速约为1000转/分钟)约两小时后，使用0.45微米孔径的聚四氟乙烯滤膜将样品溶液趁热过滤至新的3毫升玻璃小瓶中，封口后将滤液迅速置-20℃下静置，析出固体。
经检测，本实施例得到的固体为对甲苯磺酸盐晶型A。对甲苯磺酸盐晶型A的X射线粉末衍射数据如表1所示，其衍射图如图1所示。 1H NMR如图2所示，游离碱与对甲苯磺酸的摩尔比为1:1，无溶剂残留。
表1
衍射角2θ d值 强度％
6.22 14.21 100.00
9.27 9.54 34.72
9.54 9.28 3.27
13.37 6.62 7.10
14.07 6.29 27.56
14.56 6.09 7.68
15.70 5.64 3.03
16.38 5.41 12.45
16.74 5.30 16.26
18.29 4.85 12.18
18.63 4.76 64.75
18.80 4.72 17.93
19.11 4.65 29.96
19.31 4.60 12.11
19.77 4.49 15.22
20.57 4.32 4.47
21.07 4.22 7.34
21.49 4.13 27.06
22.53 3.95 25.01
23.02 3.86 1.94
23.39 3.80 2.09
24.88 3.58 4.81
25.35 3.51 2.26
26.29 3.39 1.78
26.79 3.33 9.28
27.10 3.29 4.72
27.51 3.24 4.64
28.14 3.17 2.02
28.55 3.13 3.73
28.96 3.08 6.29
29.38 3.04 3.42
30.18 2.96 1.17
30.59 2.92 0.84
31.29 2.86 1.48
31.96 2.80 1.50
32.35 2.77 1.13
32.89 2.72 2.24
34.02 2.64 1.79
35.23 2.55 1.23
36.81 2.44 0.51
37.98 2.37 1.17
39.40 2.29 1.11
实施例2：对甲苯磺酸盐晶型A的制备
室温条件下称取6.2毫克式(I)对甲苯磺酸盐化合物置于3毫升的玻璃小瓶中，加入1.0毫升甲醇/甲苯(体积比1:1)混合溶液，震荡后使用0.45微米孔径的聚四氟乙烯滤膜将样品溶液趁热过滤至新的3毫升玻璃小瓶中得到澄清溶液，将该溶液敞口置于预盛有3毫升甲基叔丁基醚的20毫升玻璃瓶中。封口后置于室温条件下气液渗透约2周时间，析出固体。
经检测，本实施例得到的固体为对甲苯磺酸盐晶型A。对甲苯磺酸盐晶型A的X射线粉末衍射数据如表2所示，其衍射图如图3所示。TGA如图4所示，DSC如图5所示，熔点约为280℃。
综合上述表征数据，推测对甲苯磺酸盐晶型A为无水晶型。
表2
衍射角2θ d值 强度％
6.22 14.20 100.00
9.27 9.54 7.55
9.53 9.28 1.28
12.48 7.09 1.58
13.36 6.63 2.18
14.14 6.26 1.08
14.56 6.09 1.76
15.58 5.69 0.21
16.28 5.45 1.15
16.73 5.30 3.05
18.28 4.85 0.46
18.64 4.76 11.74
18.79 4.72 15.26
19.12 4.64 7.77
19.82 4.48 0.47
20.49 4.34 0.41
21.49 4.13 6.09
22.53 3.95 11.47
22.97 3.87 0.84
23.74 3.75 0.43
24.86 3.58 0.65
25.28 3.52 0.39
26.62 3.35 0.29
28.18 3.17 0.41
28.53 3.13 0.39
28.95 3.08 1.94
29.40 3.04 0.73
32.92 2.72 0.50
34.01 2.64 0.23
35.17 2.55 0.22
38.13 2.36 0.54
39.40 2.29 0.54
实施例3～4：对甲苯磺酸盐晶型A的制备(气液渗透法)
室温条件下称取适量的式(I)对甲苯磺酸盐化合物固体置于3毫升的玻璃小瓶中，加入相应体积的正溶剂以溶解固体，使用0.45微米孔径的聚四氟乙烯滤膜将样品溶液过滤至新的3毫升玻璃小瓶中，敞口置于预盛有3毫升相应反溶剂的20毫升玻璃瓶中。封口后置于室温条件下气液渗透约2周时间，析出固体。若无固体析出，则将样品转移至室温条件下敞口挥发，直至有固体析出。
经检测，本实施例得到的固体均为对甲苯磺酸盐晶型A。本实施例中所涉详细试验条件如表3所示。实施例3样品的X射线粉末衍射数据如表4所示。
表3
Figure PCTCN2021098774-appb-000011
表4
衍射角2θ d值 强度％
6.22 14.22 100.00
9.28 9.53 9.19
12.48 7.09 1.37
13.35 6.63 1.86
14.11 6.28 0.93
14.58 6.08 1.81
16.31 5.44 0.98
16.73 5.30 10.96
18.63 4.76 15.05
18.77 4.73 18.31
19.10 4.65 4.90
19.79 4.49 0.90
21.49 4.14 9.97
22.53 3.95 8.53
24.89 3.58 0.83
26.98 3.30 0.29
28.95 3.08 1.91
29.43 3.04 0.73
32.95 2.72 0.59
35.22 2.55 0.48
38.10 2.36 0.65
39.39 2.29 0.38
实施例5～8：对甲苯磺酸盐晶型A的制备(缓慢挥发法)
室温条件下称取适量式(I)对甲苯磺酸盐化合物固体置3毫升玻璃小瓶中，加入相应体积的正溶剂以溶解固体，使用0.45微米孔径的聚四氟乙烯滤膜将样品溶液过滤至新的3毫升玻璃小瓶中，之后将该溶液用封口膜封好，膜上戳3-4个小孔，置于室温或50℃下缓慢挥发，直至得到固体。
经检测，本实施例得到的固体均为对甲苯磺酸盐晶型A。本实施例中所涉详细试验条件如表5所示。实施例7样品的X射线粉末衍射数据如表6所示。
表5
Figure PCTCN2021098774-appb-000012
表6
衍射角2θ d值 强度％
6.22 14.21 83.47
9.27 9.55 42.34
9.53 9.28 3.30
12.47 7.10 1.59
13.36 6.63 7.44
14.06 6.30 41.61
14.56 6.09 10.12
15.69 5.65 4.49
16.38 5.41 21.85
16.73 5.30 18.08
18.28 4.85 19.75
18.63 4.76 100.00
18.81 4.72 25.37
19.10 4.65 35.30
19.30 4.60 19.91
19.76 4.49 27.92
20.56 4.32 9.24
21.07 4.22 14.35
21.48 4.14 30.83
22.52 3.95 35.91
22.98 3.87 3.63
23.38 3.80 4.52
23.73 3.75 3.38
24.87 3.58 7.69
25.34 3.52 4.07
26.24 3.40 2.14
26.76 3.33 12.58
27.09 3.29 7.77
27.50 3.24 7.44
28.11 3.18 3.67
28.53 3.13 4.75
28.95 3.08 7.48
29.38 3.04 5.96
30.15 2.96 2.27
30.62 2.92 1.58
31.24 2.86 2.62
31.95 2.80 2.29
32.39 2.76 1.32
32.86 2.73 3.73
34.15 2.63 0.81
37.12 2.42 1.36
37.94 2.37 1.85
实施例9：对甲苯磺酸盐晶型A的制备(缓慢降温法)
室温条件下称取适量的式(I)对甲苯磺酸盐化合物固体置于3毫升的玻璃小瓶中，加入0.5毫升甲醇得到悬浊液。将该悬浊液在50℃条件下磁力搅拌(转速约为1000转/分钟)约两小时后，使用0.45微米孔径的聚四氟乙烯滤膜将样品溶液趁热过滤至新的3毫升玻璃小瓶中，封口后以0.1℃每分钟的速率从50℃降温至5℃，而后于5℃恒温静置，析出固体。
经检测，本实施例得到的固体为对甲苯磺酸盐晶型A。该样品的X射线粉末衍射数据如表7所示。
表7
衍射角2θ d值 强度％
6.22 14.21 100.00
9.27 9.54 14.44
13.38 6.62 3.07
14.15 6.26 6.33
14.56 6.08 4.21
15.74 5.63 1.29
16.40 5.40 4.54
16.75 5.29 9.40
18.39 4.82 6.01
18.63 4.76 28.56
18.78 4.72 27.10
19.10 4.65 16.85
19.41 4.57 4.30
19.84 4.48 7.03
20.62 4.31 2.45
21.15 4.20 5.63
21.50 4.13 12.62
22.52 3.95 19.82
23.43 3.80 1.48
24.92 3.57 2.93
26.82 3.32 2.83
27.59 3.23 1.95
28.65 3.12 3.41
28.94 3.08 4.93
29.38 3.04 2.89
30.26 2.95 1.01
31.33 2.86 1.41
32.02 2.80 1.03
32.90 2.72 3.57
33.99 2.64 1.46
38.04 2.37 1.49
39.39 2.29 1.52
实施例10～11：对甲苯磺酸盐晶型A的制备(快速降温试验)
室温条件下称取适量的式(I)对甲苯磺酸盐化合物固体置于3毫升的玻璃小瓶中，加入相应体积的溶剂得到悬浊液。将该悬浊液在50℃条件下磁力搅拌(转速约为1000转/分钟)约两小时后，使用0.45微米孔径的聚四氟乙烯滤膜将样品溶液趁热过滤至新的3毫升玻璃小瓶中，封口之后将该溶液迅速放入-20℃的环境中静置，约5天后析出固体。如无固体析出，则将其转移至室温下敞口挥发，直至得到固体。
经检测，本实施例得到的固体均为对甲苯磺酸盐晶型A。本实施例中所涉详细试验条件如表8所示，实施例11样品的X射线粉末衍射数据如表9所示，其衍射图如图6所示。
表8
实施例 固体质量(毫克) 溶剂(v/v/v) 体积(毫升) 实验条件
10 10.2 乙醇 1.0 -20℃静置析晶
11 10.4 甲醇/丙酮(1/1) 1.0 -20℃静置析晶
表9
衍射角2θ d值 强度％
6.22 14.20 100.00
9.27 9.54 32.41
13.36 6.63 8.16
14.08 6.29 59.96
14.55 6.09 9.57
15.70 5.64 8.23
16.40 5.41 26.01
16.74 5.30 18.72
18.30 4.85 23.53
18.64 4.76 74.69
18.86 4.71 25.15
19.10 4.65 37.16
19.31 4.60 22.00
19.77 4.49 33.19
20.57 4.32 7.83
21.08 4.21 17.05
21.49 4.14 34.43
22.53 3.95 34.55
23.38 3.80 4.92
24.90 3.58 6.73
26.77 3.33 21.88
27.11 3.29 12.14
27.52 3.24 12.31
28.56 3.13 9.71
28.97 3.08 8.94
32.86 2.73 3.38
37.94 2.37 2.82
39.39 2.29 3.19
实施例12～19：对甲苯磺酸盐晶型A的制备(反溶剂添加法)
室温条件下称取适量式(I)对甲苯磺酸盐化合物固体置于20毫升的玻璃小瓶中，加入相应体积正溶剂以得到澄清溶液。随后磁力搅拌(转速约为1000转/分钟)得到澄清溶液，并向其中逐滴加入相应的反溶剂，如固体析出，则离心分离得到固体。若加入10毫升反溶剂后仍无固体析出，则停止滴加反溶剂，将样品转移至室温下挥发，得到固体。
经检测，本实施例得到的固体均为对甲苯磺酸盐晶型A。本实施例中所涉及的详细试验条件如表10所示，实施例13样品的X射线粉末衍射数据如表11所示。
表10
Figure PCTCN2021098774-appb-000013
Figure PCTCN2021098774-appb-000014
表11
衍射角2θ d值 强度％
6.22 14.21 100.00
9.27 9.54 15.93
14.06 6.30 1.45
14.56 6.08 3.01
16.73 5.30 2.57
18.63 4.76 23.36
18.80 4.72 13.59
19.10 4.65 8.31
19.75 4.49 1.01
21.49 4.14 3.26
22.52 3.95 9.05
实施例20～24：对甲苯磺酸盐晶型A的制备(反向反溶剂添加法)
室温条件下称取适量的式(I)化合物固体置于5毫升的玻璃小瓶中，加入相应体积的正溶剂以得到澄清溶液。在20毫升的玻璃小瓶中加入相应反溶剂并磁力搅拌(转速约为1000转/分钟)，随后向其中快速加入样品溶液，析出固体。若滴加完成后无固体析出，则将样品转移至-20℃静置，析出固体。
经检测，本实施例得到的固体均为对甲苯磺酸盐晶型A。本实施例中所涉详细试验条件如表12所示，实施例23的X射线粉末衍射数据如表13所示，其衍射图如图7所示。
表12
Figure PCTCN2021098774-appb-000015
Figure PCTCN2021098774-appb-000016
表13
衍射角2θ d值 强度％
6.22 14.21 100.00
9.27 9.54 11.35
12.44 7.11 0.77
13.36 6.62 0.67
14.09 6.28 4.74
14.60 6.06 0.91
15.57 5.69 0.57
15.73 5.63 0.53
16.38 5.41 2.33
16.73 5.29 1.50
17.08 5.19 0.54
18.32 4.84 1.40
18.63 4.76 18.29
18.79 4.72 14.98
19.10 4.65 3.81
19.79 4.49 1.90
20.56 4.32 0.78
21.11 4.21 0.85
21.49 4.14 2.96
22.52 3.95 6.01
28.95 3.08 0.64
38.15 2.36 0.28
实施例25～31：对甲苯磺酸盐晶型A的制备(聚合物诱导结晶法)
室温条件下称取适量的式(I)化合物固体置于3毫升的玻璃小瓶中，加入相应体积的正溶剂以得到澄清溶液。使用0.45微米孔径的聚四氟乙烯滤膜将样品溶液过滤至新的3毫升装有相应聚合物的玻璃小瓶中，含有聚合物的混合物室温下挥发，析出固体。
经检测，本实施例得到的固体均为对甲苯磺酸盐晶型A。本实施例中所涉详细试验条件如表14所示，实施例27样品的X射线粉末衍射数据如表15所示。
表14
Figure PCTCN2021098774-appb-000017
表15
衍射角2θ d值 强度％
6.22 14.21 100.00
9.26 9.55 38.76
13.34 6.63 8.89
14.07 6.30 46.42
14.52 6.10 9.41
15.66 5.66 8.51
16.37 5.42 21.41
16.73 5.30 23.13
18.27 4.86 20.21
18.63 4.76 85.56
18.79 4.72 29.33
19.10 4.65 44.58
19.25 4.61 19.76
19.77 4.49 27.56
20.53 4.32 11.38
21.07 4.22 15.74
21.48 4.14 37.69
22.52 3.95 42.68
23.35 3.81 7.39
24.85 3.58 8.79
25.32 3.52 4.29
26.77 3.33 13.55
27.11 3.29 11.29
27.51 3.24 8.44
28.38 3.14 8.65
28.54 3.12 8.82
28.95 3.08 11.19
29.35 3.04 6.68
实施例32～38：对甲苯磺酸盐晶型A的制备(快速挥发法)
室温条件下称取适量式(I)对甲苯磺酸盐化合物固体置3毫升玻璃小瓶中，加入相应体积的正溶剂以溶解固体，使用0.45微米孔径的聚四氟乙烯滤膜将样品溶液过滤至新的3毫升玻璃小瓶中，之后将该溶液敞口置于50℃或5℃条件下敞口挥发，直至得到固体。
经检测，本实施例得到的固体均为对甲苯磺酸盐晶型A。本实施例中所涉详细试验条件如表16所示。实施例33样品的X射线粉末衍射数据如表17所示。
表16
Figure PCTCN2021098774-appb-000018
表17
衍射角2θ d值 强度％
6.22 14.21 100.00
9.27 9.54 31.72
12.45 7.10 2.72
13.35 6.63 5.68
14.07 6.29 45.06
14.56 6.08 4.18
15.70 5.64 6.05
16.38 5.41 25.53
16.74 5.29 13.33
18.29 4.85 22.22
18.64 4.76 56.62
19.10 4.65 28.22
19.30 4.60 19.04
19.77 4.49 25.08
20.54 4.32 7.33
21.08 4.22 15.29
21.49 4.14 26.77
22.52 3.95 22.76
24.91 3.58 4.98
26.77 3.33 12.69
27.06 3.29 8.17
27.51 3.24 7.64
28.54 3.13 5.88
28.97 3.08 5.87
实施例39：稳定性研究
称取采用本发明实施例1方法制备的对甲苯磺酸盐晶型A各约10毫克，敞口放置于25℃/60％RH条件以及40℃/75％RH条件的稳定箱中，在1周、2周、4周和8周后取样测XRPD及纯度，结果如表18所示，XRPD对比图如图10所示。
表18晶型A稳定性研究
Figure PCTCN2021098774-appb-000019
由结果可知，本发明晶型A在25℃/60％RH和40℃/75％RH条件下放置8周，晶型未 变，纯度均大于99％。本发明晶型A在25℃/60％RH、40℃/75％RH条件下具有较好的物理/化学稳定性。
实施例40：引湿性研究
称取采用本发明实施例1方法制备的对甲苯磺酸盐晶型A与现有技术固体各约10毫克进行动态水分吸附(DVS)测试，然后取样测XRPD。对甲苯磺酸盐晶型A的DVS如图8所示，XRPD在测试前后的晶型未发生变化，结果如图9所示。由结果可知，在80％湿度条件下，吸湿增重为0.35％，对甲苯磺酸盐晶型A略有引湿性，与现有技术相比，引湿性更低，满足药用原料药对引湿性的要求。
关于引湿性特征描述与引湿性增重的界定(中国药典2015年版附录XIX J药物引湿性试验指导原则)：
潮解：吸收足量水分形成液体
极具引湿性：引湿增重不小于15％
有引湿性：引湿增重小于15％但不小于2％
略有引湿性：引湿增重小于2％但不小于0.2％
无或几乎无引湿性：引湿增重小于0.2％。
实施例41：晶型的溶解度
将采用本发明实施例1方法制备的对甲苯磺酸盐晶型A与现有技术固体，用SGF(模拟人工胃液)、FaSSIF(空腹状态下人工肠液)、FeSSIF(饱食状态下人工肠液)和纯水分别配制成悬浊液，在1小时、2小时、4小时和24小时平衡后过滤，得到饱和溶液。通过高效液相色谱法(HPLC)测定饱和溶液中样品的含量。由结果可知，本发明晶型A在纯水、SGF、FaSSIF和FeSSIF中的溶解度如表19所示。本发明晶型A在生物介质中溶解度好，能够满足口服给药对药物溶解度的要求，与现有技术相比，溶解度更好，具有较好的应用前景。
表19
介质 1小时毫克/毫升 2小时毫克/毫升 4小时毫克/毫升 24小时毫克/毫升
H 2O 5.2622 5.3388 5.2410 5.5622
SGF 5.5375 5.9864 5.0784 5.6942
FaSSIF 7.1155 7.3099 7.2968 7.5385
FeSSIF 6.7660 7.0277 7.3408 7.7836
实施例42：晶型的可压性
采用手动压片机进行压片，压片时，选择可以压制成圆柱体片剂的圆形平冲，加入一定量的按照本发明实施1方法制备的对甲苯磺酸盐晶型A与现有技术固体，采用350MPa压力压制成圆形片剂，采用片剂硬度测定仪测试其径向破碎力(硬度，H)为18.36牛顿。采用游标卡尺测量片剂的直径(D)为6毫米，厚度为1.02毫米，利用公式T＝2H/πDL计算出晶型A的抗张强度为1.9MPa，具有较高的抗张强度，与现有技术相比，可压性更优，能够满足药物制剂工艺要求。
实施例43：晶型的固有溶出速率
分别称取采用本发明实施例1方法制备的对甲苯磺酸盐晶型A和现有技术中披露固体约100mg，倒入固有溶出模具，在5kN压力下持续1分钟，制成表面积0.5cm 2的薄片，取完整压片转移至溶出仪测试固有溶出速率，溶出条件如表18有溶出速率(Intrinsic dissolution rate,IDR)，以毫克/分钟/cm 2表示。结果表明，本发明晶型的溶出速率较现有技术中披露固体更快。
表20
溶出仪 CSE-051 Agilent 708DS
方法 浆法
介质 pH6.8磷酸盐缓冲液
介质体积 900mL
转速 100rpm
介质温度 37℃
取样点 1,2,3,4,5,10,15,20,25,30min
补充介质 No
实施例44：晶习对比研究
称取采用本发明实施例1方法制备的对甲苯磺酸盐晶型A与现有技术固体置于载玻片上，滴加少许真空硅油分散样品，然后盖上盖玻片，置于偏光显微镜下观察。本发明晶型为短棒状固体，具有良好的流动性(图11)。
实施例45：粒径分布对比研究
称取采用本发明实施例1方法制备的对甲苯磺酸盐晶型A与现有技术固体约10-30毫克，然后加入约10毫升Isopar G(含有0.2％卵磷脂)，将待测样品充分混合均匀后加入SDC进样系统中，使遮光度达到合适范围，开始实验，分别在未超声及超声30秒后进行粒径分布的测试。测试结果显示本发明对甲苯磺酸盐晶型A平均粒径约400微米，粒径分布均匀，超声前后粒径分布未见显著变化，说明样品分散较好，未发现明显的团聚。与现有技术相比，粒径分布更加均匀。
实施46：黏附性对比研究
称取采用本发明实施例1方法制备的对甲苯磺酸盐晶型A和现有技术中披露固体各约30毫克，然后加入到8毫米圆形平冲中，采用10kN的压力进行压片处理，压片后停留约半分钟，称量冲头吸附的粉末量。采用该方法连续压制两次后，记录冲头累积的最终黏附量、压制过程中的最高黏附量和平均黏附量。本发明对甲苯磺酸盐晶型A的黏附性优于现有技术中披露固体。
上述实施例只为说明本发明的技术构思及特点，其目的在于让熟悉此项技术的人士能够了解本发明的内容并据以实施，并不能以此限制本发明的保护范围。凡根据本发明精神实质所作的等效变化或修饰，都应涵盖在本发明的保护范围之内。

Claims (11)

  1. 式(I)所示化合物[(1S)-2,2-二氟环丙基][(1R，5S)-3-{2-[(1-甲基-1H-吡唑-4-基)氨基]嘧啶-4-基}-3,8-二氮杂双环[3.2.1]辛烷-8-基]甲酮的对甲基苯磺酸盐A型晶体、即对甲苯磺酸盐晶型A，其特征在于，使用Cu-Kα辐射，所述对甲苯磺酸盐晶型A的X射线粉末衍射在2θ值为6.2°±0.2°,18.6°±0.2°,9.3°±0.2°处有特征峰，
    Figure PCTCN2021098774-appb-100001
  2. 根据权利要求1所述的对甲苯磺酸盐晶型A，其X射线粉末衍射在2θ值为19.1°±0.2°,14.1°±0.2°,21.5°±0.2°中的一处或两处或三处有特征峰。
  3. 根据权利要求1或2所述的对甲苯磺酸盐晶型A，其X射线粉末衍射在2θ值为19.1°±0.2°,14.1°±0.2°,21.5°±0.2°处有特征峰。
  4. 权利要求1～3中任意一项所述的对甲苯磺酸盐晶型A的制备方法，其特征在于，
    Figure PCTCN2021098774-appb-100002
    将式(I)化合物的对甲苯磺酸盐溶解于正溶剂中，过滤后向其中逐滴加入反溶剂，得到对甲苯磺酸盐晶型A。
  5. 权利要求1～3中任意一项所述的对甲苯磺酸盐晶型A的制备方法，其特征在于，
    Figure PCTCN2021098774-appb-100003
    将式(I)化合物的对甲苯磺酸盐溶解于正溶剂中，过滤后将其快速加入反溶剂中，得到 对甲苯磺酸盐晶型A。
  6. 权利要求1～3中任意一项所述的对甲苯磺酸盐晶型A的制备方法，其特征在于，
    Figure PCTCN2021098774-appb-100004
    一定温度下将式(I)化合物的对甲苯磺酸盐溶解于挥发性溶剂中，挥发析晶，得到对甲苯磺酸盐晶型A。
  7. 权利要求1～3中任意一项所述的对甲苯磺酸盐晶型A的制备方法，其特征在于，
    Figure PCTCN2021098774-appb-100005
    将式(I)化合物的对甲苯磺酸盐溶于正溶剂中，然后置于含有反溶剂的密封环境中，渗透析晶，得到对甲苯磺酸盐晶型A。
  8. 权利要求1～3中任意一项所述的对甲苯磺酸盐晶型A的制备方法，其特征在于，
    Figure PCTCN2021098774-appb-100006
    将式(I)化合物的对甲苯磺酸盐溶于正溶剂中，高温条件下溶解平衡后过滤，降温至析出固体，得到对甲苯磺酸盐晶型A。
  9. 药物组合物，其包含权利要求1～3中任一项所述的晶体和制药学可接受的载体。
  10. 具有JAK1和TYK2通路双重抑制剂活性的药物组合物，其含有权利要求1～3中任一项所述的晶体作为有效成分。
  11. 治疗斑秃、银屑病和溃疡性结肠炎的预防药或治疗药，其含有权利要求1～3中任一项所述的晶体作为有效成分。
PCT/CN2021/098774 2020-06-09 2021-06-08 二氮杂双环类化合物的对甲苯磺酸盐新晶型及其制备方法 Ceased WO2021249367A1 (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202180081891.6A CN116802183A (zh) 2020-06-09 2021-06-08 二氮杂双环类化合物的对甲苯磺酸盐新晶型及其制备方法
US18/041,211 US20240018155A1 (en) 2020-06-09 2021-06-08 New crystal form of p-toluenesulfonate salt of diazabicyclic compound and preparation method therefor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010515404.X 2020-06-09
CN202010515404 2020-06-09

Publications (1)

Publication Number Publication Date
WO2021249367A1 true WO2021249367A1 (zh) 2021-12-16

Family

ID=78845335

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/098774 Ceased WO2021249367A1 (zh) 2020-06-09 2021-06-08 二氮杂双环类化合物的对甲苯磺酸盐新晶型及其制备方法

Country Status (3)

Country Link
US (1) US20240018155A1 (zh)
CN (1) CN116802183A (zh)
WO (1) WO2021249367A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022161507A1 (zh) * 2021-02-01 2022-08-04 杭州领业医药科技有限公司 Brepocitinib甲苯磺酸盐的晶型及其制备方法和用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107074867A (zh) * 2014-08-21 2017-08-18 辉瑞公司 作为jak抑制剂的氨基嘧啶基化合物
TW202045511A (zh) * 2019-02-15 2020-12-16 美商輝瑞股份有限公司 結晶型嘧啶基－３，８－二氮雜雙環〔３．２．１〕辛烷基甲酮化合物及其用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107074867A (zh) * 2014-08-21 2017-08-18 辉瑞公司 作为jak抑制剂的氨基嘧啶基化合物
TW202045511A (zh) * 2019-02-15 2020-12-16 美商輝瑞股份有限公司 結晶型嘧啶基－３，８－二氮雜雙環〔３．２．１〕辛烷基甲酮化合物及其用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANDREW FENSOME, CATHERINE M. AMBLER, ERIC ARNOLD, MARY ELLEN BANKER, MATTHEW F. BROWN, JILL CHRENCIK, JAMES D. CLARK, MARTIN E. DO: "Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S )-2,2-Difluorocyclopropyl)((1 R ,5 S )-3-(2-((1-methyl-1 H -pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)", JOURNAL OF MEDICINAL CHEMISTRY, vol. 61, no. 19, 11 October 2018 (2018-10-11), US , pages 8597 - 8612, XP055688622, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.8b00917 *
TANG, XIAO-NAN ET AL.: "Research Progress of Small-Molecule Drugs Targeting JAK in Autoimmune Diseases", ACTA PHARMACEUTICA SINICA, vol. 53, no. 10, 12 October 2018 (2018-10-12), pages 1591 - 1597, XP055879142, ISSN: 0513-4870 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022161507A1 (zh) * 2021-02-01 2022-08-04 杭州领业医药科技有限公司 Brepocitinib甲苯磺酸盐的晶型及其制备方法和用途

Also Published As

Publication number Publication date
CN116802183A (zh) 2023-09-22
US20240018155A1 (en) 2024-01-18

Similar Documents

Publication Publication Date Title
Sohn et al. Characterization of physicochemical properties of ferulic acid
WO2019052133A1 (zh) Gsk1278863的晶型及其制备方法和制药用途
WO2017215617A1 (zh) 奥扎莫德的晶型、其盐酸盐的晶型及其制备方法
CN111094290B (zh) 瑞博西尼的单琥珀酸盐晶型及其制备方法和用途
WO2018050091A1 (zh) 奥扎莫德盐酸盐的晶型及其制备方法
WO2021218948A1 (zh) 磺酰胺类化合物的晶型及其制备方法
WO2019242439A1 (zh) Arn-509的晶型及其制备方法和用途
WO2020057622A1 (zh) 卡博替尼苹果酸盐晶型及其制备方法和用途
WO2022121670A1 (zh) Tolebrutinib的晶型及其制备方法和用途
JP2020500912A (ja) ブロモドメインタンパク質阻害薬の結晶形及びその製造方法並びに用途
EP3677575A1 (en) Crystalline form of ozanimod hydrochloride and preparation method therefor
WO2021129467A1 (zh) 一种bms-986165晶型及其制备方法和用途
CN114195740B (zh) 卡利拉嗪药用盐及其晶型、制备方法和应用
WO2021249367A1 (zh) 二氮杂双环类化合物的对甲苯磺酸盐新晶型及其制备方法
CN116262746A (zh) 阿伐曲泊帕的马来酸盐新晶型及其制备方法
WO2023280132A1 (zh) 氧代二氢咪唑并吡啶类化合物的晶型及其制备方法
WO2023025268A1 (zh) 哒嗪甲酰胺类化合物的晶型及其制备方法
WO2019205812A1 (zh) Acalabrutinib的新晶型及其制备方法和用途
WO2021233461A1 (zh) 苯并噻唑类化合物的新晶型及其制备方法
WO2019149262A1 (zh) Sb-939的晶型及其制备方法和用途
CN116456986A (zh) 一种喹唑啉酮衍生物的新晶型及其制备方法
WO2023109939A1 (zh) 吡啶类衍生物的晶型及其制备方法
WO2022007752A1 (zh) 苯甲酰胺类化合物及其二盐酸盐的新晶型及其制备方法
WO2022089620A1 (zh) 吲哚基甲酰胺类化合物的新晶型及其制备方法
WO2022122009A1 (zh) 吡咯类衍生化合物的晶型及其制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21820900

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 202180081891.6

Country of ref document: CN

Ref document number: 18041211

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 21820900

Country of ref document: EP

Kind code of ref document: A1